Long-term follow-up of insulin autoimmune syndrome in an elderly patient

Hiroshi Yoshino1,2 | Kyoko Kawakami2 | Kenji Kohriyama3 | Gen Yoshino2 | Shinji Matsunaga1 | Hajime Takechi1

1Department of Geriatrics and Cognitive Disorders, Fujita Health University School of Medicine, Toyoake, Japan
2Center for Diabetes, Shin-suma General Hospital, Kobe, Japan
3Department of Internal Medicine, Shin-suma General Hospital, Kobe, Japan

Correspondence
Hiroshi Yoshino, Department of Geriatrics and Cognitive Disorders, Fujita Health University School of Medicine, 98-1, Dengakubo, Kutsugake-cho, Toyoake City, Aichi 470-1192, Japan.
Email: hgmedktree2236@yahoo.co.jp

Abstract
An 84-year-old man was admitted to our hospital. His blood glucose level was 20 mg/dL. Since laboratory tests showed high titers of insulin antibodies, insulin autoimmune syndrome (IAS) was diagnosed. In order to avoid hypoglycemia, steroids can be effective in the long-term management of IAS in elderly patients.

KEYWORDS
anti-insulin antibodies, elderly, insulin autoimmune syndrome, steroid

1 | INTRODUCTION

An 84-year-old man was admitted to our hospital. His blood glucose level was 20 mg/dL. Since laboratory tests showed high titers of insulin antibodies, insulin autoimmune syndrome (IAS) was diagnosed. In order to avoid hypoglycemia, steroids can be effective in the long-term management of IAS in elderly patients.

Insulin autoimmune syndrome (IAS), also called Hirata’s disease (HD), was first reported in 1970.1 IAS is a disease characterized by hyperinsulinemic hypoglycemia, elevated insulin autoantibody titers, without prior exposure to exogenous insulin and no pathological abnormalities of the pancreatic islets. However, the pathophysiology of IAS is still poorly understood. It is likely to be associated with autoimmune diseases or plasma cell dyscrasias. It has been suggested that sulphydryl group drugs divide the disulfide bond of insulin and enhance its immunogenic properties.2 From the first IAS report up to 2007, 380 cases of IAS were identified by Uchigata et al.3 IAS is known to be more common among the Asian population. We reported a case of IAS in an elderly patient in 20154 and follow-up of the patient thereafter. Seven years after his diagnosis, his high titer of anti-insulin antibodies decreased significantly due to steroid therapy. Furthermore, some critical points for successful long-term control of blood glucose in IAS patients are discussed.

2 | CASE PRESENTATION

In December 2012, an 84-year-old man was admitted to Shin-suma General Hospital. On arrival, he was unconscious and his blood glucose level was 20 (range 70-110) mg/dL. Laboratory investigations revealed: glycated hemoglobin (HbA1c:NGSP) 6.6 (range 4.7-6.2) %, high titers of insulin antibodies (≦5%: bound/total), and immunoreactive insulin (IRI) 7800 (range 5-15) mU/L. A 75 g oral glucose tolerance test (OGTT) showed impaired glucose tolerance...
(Table 1). The patient experienced persistent hypoglycemia (Figure 1A). Low affinity constant and a high binding capacity of autoantibodies were revealed by Scatchard analysis (Figure 2A). Moreover, his human leukocyte antigen (HLA) was DRB1*04:03, which has been reported to be associated with IAS previously. Therefore, he was diagnosed with IAS. He had hypertension, prostatic hypertrophy, and constipation. Onset of cerebral infarction occurred 2 years previously. Before admission to the hospital, clopidogrel, eicosapentaenoic acid, magnesium oxide, cilostazol, irbesartan, and silodosin were prescribed. After admission, eicosapentaenoic acid and magnesium oxide were discontinued. The patient was maintained on frequent small meals to prevent rapid elevation of plasma glucose levels. However, a month later, the patient still experienced attacks of hypoglycemia and his insulin-binding antibody titer remained elevated. We initiated steroid therapy to suppress production of the autoimmune antibodies causing the hypoglycemia attacks. Prednisolone (PSL) was started at a dose of 30 mg/d for the first 5 days, and the dosage was tapered 5 mg/d at 5-day intervals. He did not experience any further hypoglycemic episodes (Figure 1B). The affinity constant and binding capacity of the autoantibodies also improved (Figure 2B). There were no new cerebrovascular disorders. Therefore, clopidogrel was withdrawn in February 2013. PSL was reduced to 2.5 mg/d in September 2013. The patient did not experience any steroid-related side effects such as, osteoporosis, hypertension, serious infection, or muscle weakness. His anti-insulin antibody levels decreased gradually. In January 2019, the patient’s anti-insulin antibodies were significantly reduced to 18.1% (Figure 3) and his IRI was 7.0 mU/L. His fasting blood glucose was maintained between 88 and 92 mg/dL. The patient did not experience any hypoglycemic episodes. Therefore, dose reduction of PSL was commenced. Simultaneously, his adrenal function was monitored to avoid adrenal insufficiency. Basal plasma adrenocorticotropic hormone (ACTH) was 99.8 (range 7.2-63.3) pg/mL with serum cortisol of 16.2 (range 2.7-15.5) μg/dL. Rapid-ACTH stimulation test revealed that his adrenal function was normal (serum cortisol was 13.6, 17.2, 17.8, and 19.4 μg/dL at 30, 60, 120, and 180 min, respectively).

**Table 1** 75 g oral glucose tolerance test (OGTT)

| Time (min) | 0  | 60 | 120 | 180 |
|-----------|----|----|-----|-----|
| BG (mg/dL) | 28 | 204| 180 | 84  |
| IRI (μIU/L)| 7800 | 7720 | 8890 | 9570 |

Abbreviations: BG, Blood glucose; IRI, Immunoreactive insulin.

**Figure 1** Twenty-four-hour glucose profile using a continuous glucose monitoring system. A, On admission. B, After 9-mo follow-up. Blue arrow indicates intravenous injection of 5% glucose. Red arrow indicates p.o of 10 g glucose. Black arrows indicates divided meal intake. p.o, per os.
15.8 and 18.6 μg/dL at 0, 30, and 60 minutes, respectively). Finally, PSL dose was tapered to 1 mg/d in September 2019 (Figure 3).

3 | DISCUSSION

From 1994 to 2010, Kondou et al. reported 120 IAS cases, 14% of which were elderly patients aged 75 years or older, and there were no cases of typical drug-related IAS. In 2017, Rajapal et al. reported a case of clopidogrel-induced IAS. The chemical structure of clopidogrel does not include sulphydryl, but its active metabolite possesses a sulphydryl group. Management of IAS may include: discontinuation of the offending drug, a low-carbohydrate diet, or often the use of glucocorticoids. Recently, IAS was successfully managed with rituximab. Oral steroid therapy is one of the lines of treatment of IAS. It has been attempted to lower the titer of insulin-binding antibody, but some cases showed a high titer of insulin-binding antibody or high immunoreactive insulin for long periods. Our case also had a high titer of insulin-binding antibody. Therefore, low-dose PSL therapy was continued to avoid relapse of hypoglycemia. According to Gomez et al., one of the mechanisms of glucocorticoids in the management of IAS is through the elevation of blood glucose caused by insulin resistance. Other factors involved in this mechanism are unclear to our knowledge. In 1987, a Japanese case report mentioned IAS patients under chronic exogenous glucocorticoid excess. Therefore, insulin binding to monocytes increased due to increased receptor numbers. In addition, under endogenous steroid excess, increased affinity for insulin receptors leads to increasing insulin binding to monocytes. Therefore, glucocorticoid therapy could reduce the levels of insulin autoantibodies. Glucocorticoid therapy revealed a significant effect in our case. However, glucocorticoid-induced adrenal insufficiency is a serious adverse effect.
effect of steroid therapy.\textsuperscript{14} Before reducing the dose of PSL, we evaluated adrenal function. According to Fujio et al.,\textsuperscript{15} in the low-dose (5-20 mg/d PSL) group, basal ACTH and cortisol levels were also significantly decreased by glucocorticoid therapy, but the amount of change of ACTH and cortisol was unchanged for at least 4 weeks.

4 | CONCLUSION

Steroids can be effective in the long-term management of IAS in elderly patients. We emphasize that under physician control of steroids, dose monitoring of adrenal function is an important matter during management of IAS.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTION

HY is responsible for database search and writing of the article. KyK, KeK, GY, SM, and HT is responsible for correction of the article and supervision.

REFERENCES

1. Hirata Y, Ishizu H. Elevated insulin-binding capacity of serum proteins in a case with spontaneous hypoglycemia and mild diabetes not treated with insulin. Tohoku J Exp Med. 1972;107:277-286.
2. Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune forms of hypoglycemia. Medicine (Baltimore). 2009;88(3):141-153.
3. Uchigata Y, Hirata Y, Iwamoto Y. Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract. 2009;83:e19-e20.
4. Yoshino H, Kawakami K, Watanabe T, Yoshino G, Kohriyama K. A case of insulin autoimmune syndrome in an elderly patient. Eur Geriatr Med. 2015;6:85-86.
5. Kondou S, Hidaka S, Kashima J, et al. Insulin autoimmune syndrome in an 89-year-old woman: the oldest age of onset ever to be reported in Japan. J Japan Diabetes Soc. 2013;56(4):227-234. (In Japanese, abstract in English).
6. Rajapal A, Kassem LS, Mosco-Cordero M, Arafa BM. Clopidogrel-induced insulin autoimmune syndrome: a newly recognized cause of hypoglycemia in a patient without diabetes. J Endocr Soc. 2017;1(9):1217-1223.
7. Saxson DR, McDermott MT, Michaels AW. Novel management of insulin autoimmune syndrome with rituximab and continuous glucose monitoring. J Clin Endocrinol Metab. 2016;101(5):1931-1934.
8. Sakai K, Handa M, Nakamura R, et al. A case of spontaneous hypoglycemia associated with idiopathic insulin autoimmune syndrome successfully treated with methylprednisolone pulse therapy. J Japan Diabetes Soc. 1994;37(6):419-424. (In Japanese, abstract in English).
9. Redmon JB, Nutall FQ. Autoimmune hypoglycemia. Endocrinol Metab Clin North Am. 1999;28(3):603-618.
10. Ichikawa K, Nishi Y, Hashizume K, et al. A case of autoimmune insulin antibody syndrome associated with polymyositis, empty sella and apparent high urinary output of immunoreactive insulin. Endocrinoil Japan. 1992;39(3):307-313.
11. Wong SL, Priestman A, Holmes DT. Recurrent hypoglycemia from insulin autoimmune syndrome. J Gen Intern Med. 2014;29(1):250-254.
12. Gomez Cruz MJ, Jabbar M, Saini N, et al. Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. Pediatr Diabetes. 2012;13(8):652-655.
13. Ohtsuka Y, Kondo T, Shimada M., et al. Erythrocyte insulin receptor in insulin autoimmune syndrome: effects of corticosteroid therapy. Tohoku J Exp Med. 1987;151(2):181-190.
14. Dinsen S, Baslund B, Klose M, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. 2013;24(8):714-720.
15. Fujio N, Masuoka S, Shikano K, Kusunoki N, Nanki T, Kawai S. Apparent hypothalamic- pituitary-adrenal axis suppression via reduction of interleukin-6 by glucocorticoid therapy in systemic autoimmune diseases. PLoS One. 2016;11(12):e0167854.

How to cite this article: Yoshino H, Kawakami K, Kohriyama K, Yoshino G, Matsuoka S, Takechi H. Long-term follow-up of insulin autoimmune syndrome in an elderly patient. Clin Case Rep. 2020;8:2940–2943. https://doi.org/10.1002/ccr3.3150